50 related articles for article (PubMed ID: 7815887)
1. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?
Orscheschek K; Merz H; Hell J; Binder T; Bartels H; Feller AC
Lancet; 1995 Jan; 345(8942):87-90. PubMed ID: 7815887
[TBL] [Abstract][Full Text] [Related]
2. ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma.
Jaye DL; Feldman AL
Blood; 2023 Apr; 141(17):2160. PubMed ID: 37103947
[No Abstract] [Full Text] [Related]
3. Prognostic value of minimal disseminated disease assessed using digital polymerase chain reaction for 3'
Fukano R; Iijima-Yamashita Y; Iwafuchi H; Nakazawa A; Saito AM; Takimoto T; Sekimizu M; Suehiro Y; Yamasaki T; Hasegawa S; Mori T; Horibe K
Haematologica; 2024 Feb; 109(2):652-656. PubMed ID: 37675509
[No Abstract] [Full Text] [Related]
4. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity in cancer treatment: An overview.
Santos MLC; de Brito BB; da Silva FAF; Botelho ACDS; de Melo FF
World J Clin Oncol; 2020 Apr; 11(4):190-204. PubMed ID: 32355641
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Rocco D; Battiloro C; Della Gravara L; Gridelli C
Drug Saf; 2019 Feb; 42(2):199-209. PubMed ID: 30649741
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Hirota T; Muraki S; Ieiri I
Clin Pharmacokinet; 2019 Apr; 58(4):403-420. PubMed ID: 29915924
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
[TBL] [Abstract][Full Text] [Related]
9. The renal effects of ALK inhibitors.
Izzedine H; El-Fekih RK; Perazella MA
Invest New Drugs; 2016 Oct; 34(5):643-9. PubMed ID: 27468827
[TBL] [Abstract][Full Text] [Related]
10. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Sullivan I; Planchard D
Ther Adv Med Oncol; 2016 Jan; 8(1):32-47. PubMed ID: 26753004
[TBL] [Abstract][Full Text] [Related]
11. Novel ALK inhibitors in clinical use and development.
Iragavarapu C; Mustafa M; Akinleye A; Furqan M; Mittal V; Cang S; Liu D
J Hematol Oncol; 2015 Feb; 8():17. PubMed ID: 25888090
[TBL] [Abstract][Full Text] [Related]
12. The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.
Sozzi G; Martelli MP; Conte D; Modena P; Pettirossi V; Pileri SA; Falini B
Haematologica; 2009 Sep; 94(9):1307-11. PubMed ID: 19734424
[TBL] [Abstract][Full Text] [Related]
13. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
Martelli MP; Sozzi G; Hernandez L; Pettirossi V; Navarro A; Conte D; Gasparini P; Perrone F; Modena P; Pastorino U; Carbone A; Fabbri A; Sidoni A; Nakamura S; Gambacorta M; Fernández PL; Ramirez J; Chan JK; Grigioni WF; Campo E; Pileri SA; Falini B
Am J Pathol; 2009 Feb; 174(2):661-70. PubMed ID: 19147828
[TBL] [Abstract][Full Text] [Related]
14. Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archival tissue.
Tan LH; Do E; Tan SY; Chong SM; Koay ES
Mol Diagn; 2004; 8(4):213-29. PubMed ID: 15887977
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin's lymphoma: the pathologist's viewpoint.
Pileri SA; Ascani S; Leoncini L; Sabattini E; Zinzani PL; Piccaluga PP; Pileri A; Giunti M; Falini B; Bolis GB; Stein H
J Clin Pathol; 2002 Mar; 55(3):162-76. PubMed ID: 11896065
[TBL] [Abstract][Full Text] [Related]
16. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.
Maes B; Vanhentenrijk V; Wlodarska I; Cools J; Peeters B; Marynen P; de Wolf-Peeters C
Am J Pathol; 2001 Jun; 158(6):2185-93. PubMed ID: 11395396
[TBL] [Abstract][Full Text] [Related]
17. Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.
Merup M
Med Oncol; 1998 Jul; 15(2):79-88. PubMed ID: 9789214
[No Abstract] [Full Text] [Related]
18. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.
Pittaluga S; Wlodarska I; Pulford K; Campo E; Morris SW; Van den Berghe H; De Wolf-Peeters C
Am J Pathol; 1997 Aug; 151(2):343-51. PubMed ID: 9250148
[TBL] [Abstract][Full Text] [Related]
19. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.
Lucey DR; Clerici M; Shearer GM
Clin Microbiol Rev; 1996 Oct; 9(4):532-62. PubMed ID: 8894351
[TBL] [Abstract][Full Text] [Related]
20. Translocation t(2;5) is not a primary event in Hodgkin's disease. Simultaneous immunophenotyping and interphase cytogenetics.
Weber-Matthiesen K; Deerberg-Wittram J; Rosenwald A; Poetsch M; Grote W; Schlegelberger B
Am J Pathol; 1996 Aug; 149(2):463-8. PubMed ID: 8701985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
